Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (TBPH), sold 13,314 shares at $16.39 ($218K) on 2026-06-15, disclosed to the SEC on 2026-06-17.
Scheduled sale ($218k) by SVP, COMM & MEDICAL AFFAIRS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.38 | 3,328 | $55K | 25.0% |
| 2 | $16.39 | 6,657 | $109K | 50.0% |
| 3 | $16.39 | 3,329 | $55K | 25.0% |
| Total | $16.39 avg | 13,314 | $218K | 100% |
| Filing → |
| TBPH | SELL | 2025-12-05 | $1.2M | — | Filing → |
| TBPH | SELL | 2025-07-16 | $174K | — | Filing → |
| TBPH | SELL | 2025-06-04 | $264K | — | Filing → |